Article
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
Cancer research - 15 May 2009
Wee Susan, Jagani Zainab, Xiang Kay Xiaoqin, Loo Alice, Dorsch Marion, Yao Yung-Mae, Sellers William R, Lengauer Christoph, Stegmeier Frank
Abstract excerpt
The RAS pathway is one of the most frequently deregulated pathways in cancer. RAS signals through multiple effector pathways, including the RAF/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK MAPK and phosphatidylinositol 3-kinase (PI3K)-AKT signaling cascades. The oncogenic potential of these effector pathways is illustrated by the frequent occurrence of...
Topics
- Animals
- Antineoplastic Agents
- Apoptosis
- Benzamides
- Cell Division
- Cell Line, Tumor
- Colonic Neoplasms
- Diphenylamine
- Doxycycline
- Enzyme Activation
- Female